Indeed, once AAV patients with kidney disease achieve complete remission, they have a much lower relapse risk (usually patients with MPA/anti-MPO+), compared with those with lung disease (usually patients with GPA/anti-PR3+) [31]. This evidence concerns the gene PRTN3 and lung disorder.